Santen Pharmaceutical Co., Ltd. · TSE:4536
Santen Pharmaceutical — J.P. Morgan Healthcare Conference 2020
19 slides from Santen Pharmaceutical's conference presentation, Jan 13, 2020
Slide 1: Focus on the Eye: Toward the Next Growth Phase
Focus on the Eye: Toward the Next Growth Phase Shigeo Taniuchi President and COO Santen Pharmaceutical Co., Ltd. J.P. Morgan Healthcare Conference January 13, 2020 Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved.
Slide 2: Disclosure Notice
Disclosure Notice • Information given in presentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts. • Business performance
Slide 3: Specialized Ophthalmology Company with a History of 130 Years
Specialized Ophthalmology Company with a History of 130 Years Established in 1890 Headquarters in Osaka, Japan Total sales $2.1 billion in FY2018* ＞ 60 Distribution Region 3 Plants 4,000 30% Employees Overseas Sales *US$1=JPY110.99 Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights res
Slide 4: Santen's Values
Santen’s Values 1 1 “ Exploring the secrets and mechanisms of nature in order to contribute to people’s health” Santen’s original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius. We think carefully about what is essential, decide clearly what we shoul
Slide 5: Focus on the Eye: Eyes are an important organ
Focus on the Eye: Toward the Next Growth Phase 1 Eyes are an important organ 2 Growth in our business 3 New business domains Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 4
Slide 6: Eyes: An Important Organ Vital to Everyday Life
Eyes: An Important Organ Vital to Everyday Life “Vision plays a critical role in every facet and stage of life” Source: WHO World report on vision Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 5
Slide 7: Globally, the Number of People with Vision Impairments is Increasing
Globally, the Number of People with Vision Impairments is Increasing Visually Impaired Global population growth People Aging Lifestyle change Environmental issues 2.2 billion Source: WHO World report on vision Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 6
Slide 8: Growth in our business
Focus on the Eye: Toward the Next Growth Phase 1 Eyes are an important organ 2 Growth in our business 3 New business domains Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 7
Slide 9: US: Aiming for Growth with Differentiated Products
US: Aiming for Growth with Differentiated Products Differentiated pipeline / products US Tailored strategy for entering the US Realizing profitability and growth Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 8
Slide 10: Building on Strengths in Japan and EMEA
Building on Strengths in Japan and EMEA* Global Influencer High market share and know-how Sustainable -Academia and KOLs Manufacturing, growth -Regulatory expertise quality assurance Market presence capability Japan EMEA * Europe, the Middle East and Africa Copyright© 2020 Santen Pharmaceuti
Slide 11: Japan: Extension of Eylea Sales Contract and Launch of Alesion LX
Japan: Extension of Eylea* Sales Contract and Launch of Alesion LX Alesion LX Strong business base *Eylea: Co-promoted product of Bayer Yakuhin, Ltd. (MAH) Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 10
Slide 12: China / Asia: Unlocking Potential for Further Growth
China / Asia: Unlocking Potential for Further Growth Improving 4 Billion Aging Diagnosis Population Population and Access Source: UN World Population Prospects 2019 Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 11
Slide 13: Establishment of a Second Plant in Suzhou, China
Establishment of a Second Plant in Suzhou, China to Meet Demand from Increase in Patients Our Suzhou First Plant in China Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 12
Slide 14: New business domains
Focus on the Eye: Toward the Next Growth Phase 1 Eyes are an important organ 2 Growth in our business 3 New business domains Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 13
Slide 15: Tackling Unmet Needs: Myopia
Tackling Unmet Needs: Myopia Myopia Patients (billions) 3.4 DE-127: Low dose atropine 1.4 2000 2010 2020 2030 High myopia : 0.5 billion in 2030 Phase 2 trial met Vision loss primary endpoint Economic loss Source: WHO World report on vision Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights r
Slide 16: Tackling Unmet Needs: Ophthalmic Rare Diseases
Tackling Unmet Needs: Ophthalmic Rare Diseases Inherited retinal diseases, etc. Gene Therapy Vision loss / blindness Source: US National Library of Medicine National Institutes of Health Translational Vision & Science Technology https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052953/ Copyright© 2020 S
Slide 17: Partnership with ITU
Partnership with ITU To support ITU and WHO for “Be He@lthy, Be Mobile” Raise awareness of the prevention and management of non-communicable diseases ITU: International Telecommunication Union (a specialized agency of the United Nations) WHO: World Health Organization Copyright© 2020 Santen Pharmace
Slide 18: Focus on the Eye: Toward the Next Growth Phase
Focus on the Eye: Toward the Next Growth Phase Increase in ophthalmic patients Aim to resolve issues in the ophthalmology field Taking on the challenge of new fields Copyright© 2020 Santen Pharmaceutical Co., Ltd. All rights reserved. 17
Slide 19: Santen
Santen A Clear Vision For Life™ V2.1
Santen Pharmaceutical — J.P. Morgan Healthcare Conference 2020 on 6ix